People who use cannabis regularly tend to have smaller waistlines than those who don’t – a result so consistent that researchers have had to take it seriously.

What nobody had done was test which part of the plant causes it. A new study found that the compound cannabis is most famous for – the one that causes the high – isn’t the part doing the metabolic work.

That contradiction has been sitting in public health research for years.

Population surveys keep finding that regular cannabis users have lower body weight, smaller waistlines, and lower fasting insulin than non-users.

A paper drawing on a sample of nearly 5,000 American adults reported the pattern clearly, even after researchers controlled for diet and physical activity. No clean explanation followed.

Cannabis increases appetite – regular users eat several hundred more calories daily than non-users. So how do their bodies stay leaner and end up with lower diabetes rates?

Dr. Nicholas V. DiPatrizio, a professor of biomedical sciences at the University of California, Riverside (UCR) School of Medicine, has spent years chasing that question.

His team designed an experiment to test obese mice. The animals were fed a high-fat, high-sugar diet built to mimic what a lot of Americans actually eat. The mice gained weight. Their blood sugar control got worse.

Next, the researchers split the group. One set received pure delta-9 THC, the intoxicating compound most associated with cannabis.

The other set received a whole-plant extract containing the same THC dose plus a mix of other naturally occurring cannabinoids.

A third group, treated only with the vehicle solution used to dissolve the drugs, served as the control.

Behind the simple design sat a sharp question: does THC do the metabolic work alone?

Two weeks of treatment left mice in both cannabis groups noticeably leaner than the controls.

The dose was modest, the appetite effects mild, and the weight loss landed across body composition readings the team took.

If the question had stopped at fat loss, THC would have looked sufficient. Pure THC slimmed the mice as well as the full extract did.

The metabolic numbers told a different story. When the researchers ran glucose tolerance tests, the THC-only mice had not improved.

Their blood sugar still spiked and stayed high, the signature of impaired glucose control that defines type 2 diabetes.

The whole-extract mice did improve. Their glucose curves looked closer to those of a lean, healthy animal.

For a clue to why, the team looked at the chemical conversation between fat tissue and the pancreas.

Fat cells release hormones like leptin and adiponectin that tell the pancreas how much insulin to make.

In obesity, that conversation breaks down. The signals become harder to read, and blood sugar starts to climb. Eventually the system tips into type 2 diabetes.

Dr. DiPatrizio’s team measured specific hormones circulating between fat tissue and the pancreas.

In mice that received the full extract, those markers shifted toward healthier levels. In THC-only mice, they didn’t budge.

The extract held more than just THC. It also carried tetrahydrocannabivarin, cannabigerol, cannabinol, and CBD – minor cannabinoids that have drawn growing research interest.

A 2016 human trial of 62 patients with type 2 diabetes found that tetrahydrocannabivarin, taken twice daily for 13 weeks, lowered blood sugar levels and improved how the pancreas handled glucose. THC did neither.

“THC alone is not responsible for the metabolic benefits associated with cannabis use,” said Dr. DiPatrizio. “Other compounds in the plant appear to play a critical role.”

The researchers did not pinpoint a specific compound. The extract contained many of them.

Dr. DiPatrizio’s lab now intends to break the extract apart, one compound at a time.

“We’re not suggesting people should use cannabis to manage weight or diabetes,” said Dr. DiPatrizio.

The aim is a targeted therapy without the high.

Until this study, no one had cleanly separated the metabolic benefits of cannabis from its primary psychoactive compound. Now there’s evidence in living animals.

The edge cannabis users seem to enjoy doesn’t come from THC.

Earlier rodent research had already hinted at this – tetrahydrocannabivarin alone improved blood sugar control in obese mice without changing their body weight.

The new work puts the puzzle pieces together inside one living animal.

If future studies confirm which compounds restore the conversation between fat and pancreas, drug developers could chase a clean therapy for type 2 diabetes that skips the intoxicating effects entirely.

Researchers studying the cannabis paradox for two decades finally have a credible biological story to test in people.

The study is published in The Journal of Physiology.

—–

Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates.

Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.

—–